New Mayo Clinic data shows TissueCypher test improves Barrett's esophagus risk assessment and patient care.

Researchers at Mayo Clinic presented data at DDW 2026 demonstrating that the TissueCypher molecular test enhances risk stratification for Barrett's esophagus patients. The test better predicts progression to serious conditions like high-grade dysplasia or esophageal cancer compared to traditional methods, leading to changes in surveillance intervals for over half of patients. This allows for more personalized, risk-aligned management, potentially improving outcomes by escalating care for higher-risk patients and reducing unnecessary procedures for lower-risk individuals. The findings support integrating TissueCypher into clinical practice to guide more effective patient monitoring and treatment decisions.